At the news
? MIXEDIMPACT 6/10 8-K filed Jul 31, 2026 at 07:03 ET
Moderna reported Q2 2026 revenue of $145M (vs $103.9M consensus) and GAAP EPS of -$1.97 (vs -$2.06 consensus), a modest beat on both lines. The company reiterated its plan for up to 10% revenue growth in 2026 and improved its operating expense and year-end cash guidance. However, the norovirus vaccine candidate mRNA-1403 failed a Phase 3 interim analysis, a significant pipeline setback that will likely overshadow the financial beat and weigh on sentiment.
- Q2 2026 revenue of $145M, up 2% YoY from $142M, beating consensus of $103.9M.
- GAAP EPS of -$1.97, beating consensus of -$2.06 by 4.4%.
- Norovirus vaccine candidate mRNA-1403 failed Phase 3 interim analysis; trial ongoing with additional cohort enrollment.
- 2026 R&D expense guidance lowered to ~$2.9B from ~$3.0B; year-end cash guidance improved to $4.7-5.2B.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access